Therapy Detail

Therapy Name Mitomycin C + Valproic acid
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mitomycin C Mitozytrex Chemotherapy - Alkylating 14 Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary).
Valproic acid Depakene Depacon|Valproate Sodium HDAC Inhibitor 35 Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon cancer not applicable Mitomycin C + Valproic acid Preclinical Actionable In a preclinical study, Depakene (valproic acid), in combination with Mitozytrex (mitomycin C), inhibited cell viability of colon cancer cells isolated from patients (PMID: 17024798). 17024798
Clinical Trial Phase Therapies Title Recruitment Status